Bronchopulmonary dysplasia: Pathophysiology and potential anti-inflammatory therapies

Area of Science:

• Neonatal Medicine
• Pulmonology
• Pharmacology

Background:

• Bronchopulmonary dysplasia (BPD) pathogenesis is strongly linked to inflammation in preterm infant lungs.
• Inflammation can originate from intrauterine sources or postnatal respiratory support.
• Identifying effective anti-inflammatory strategies is critical for BPD prevention and treatment.

Purpose of the Study:

• To review current steroidal and non-steroidal therapeutic options for neonatal pulmonary inflammation.
• To explore the efficacy of these treatments in preventing or managing BPD.
• To provide an overview of pharmacological interventions targeting lung inflammation in preterm neonates.

Main Methods:

• Systematic literature review of studies on anti-inflammatory therapies for BPD.
• Analysis of clinical trials and research investigating steroidal and non-steroidal agents.
• Synthesis of evidence regarding treatment outcomes and safety profiles.

Main Results:

• Steroidal therapies have demonstrated efficacy in reducing BPD incidence and severity.
• Non-steroidal anti-inflammatory drugs show potential but require further investigation.
• The choice of therapy depends on the specific clinical context and inflammatory triggers.

Conclusions:

• Targeting neonatal pulmonary inflammation is a key strategy in managing BPD.
• Both steroidal and non-steroidal agents offer therapeutic possibilities.
• Further research is needed to optimize treatment protocols and expand non-steroidal options for BPD.